A more efficient DNA technology to detect and treat infectious diseases and cancer has been developed by researchers at the Institute of Bioengineering and Nanotechnology (IBN) of A*STAR.
The researchers improved on existing technologies to create a modified single-stranded DNA molecule called aptamer. DNA aptamers are ideal for pharmaceutical applications because they can specifically bind to any molecular target in the body such as proteins, viruses, bacteria and cells.
Once DNA aptamers are artificially generated for each target, they will bind to it and inhibit its activity. This makes DNA aptamers a promising technology for disease detection and drug delivery. But no DNA aptamers have been approved for clinical use yet because current aptamers do not bind well to molecular targets and are easily digested by enzymes.
“To overcome these challenges, we have created a DNA aptamer with strong binding ability and stability with superior efficacy. We hope to use our DNA aptamers as the platform technology for diagnostics and new drug development,” said IBN Executive Director Professor Jackie Y. Ying.
This study, led by IBN Principal Research Scientist and Team Leader Dr Ichiro Hirao, was recently published in the journal, Scientific Reports.
To tackle the weak binding problem, the research team added a new artificial component called unnatural base to a standard DNA aptamer, which typically has four components. The addition of the fifth component greatly enhanced the binding ability to the molecular target by 100 times as compared to conventional DNA aptamers. Furthermore, to prevent the aptamer from being digested easily by enzymes, a unique and small DNA called ‘mini-hairpin DNA’ was added to the DNA aptamer.
Dr Hirao explained, “The mini-hairpin DNAs have an unusually stable and compact stem-loop structure, like a hairpin, of small DNA fragments. Their structure strongly resists the digestive enzymes, so I added them to specific positions on the DNA aptamer to act as a protective shield. Usually DNAs are digested within one hour in blood at body temperature. With the mini-hairpin DNA, our DNA aptamers can survive for days instead of hours. This is important for pharmaceutical applications, which require the therapeutic to remain in the body for a longer period.”
If successfully commercialized, DNA aptamers could replace or complement the existing use of antibodies in drugs for targeted disease treatment. Like aptamers, antibodies bind to targets in the body, but often cause undesirable immune response and are not easy to mass produce with high quality.
“We can now generate very promising DNA aptamers for clinical use. Our aptamers are more efficient, and lower in cost and toxicity compared to conventional methods. The next step of our research is to use the aptamers to detect and deactivate target molecules and cells that cause infectious diseases, such as dengue, malaria and Methicillin-resistant Staphylococcus aureus, as well as cancer,” added Dr Hirao.
The Latest on: DNA technology
via Google News
The Latest on: DNA technology
- DNA metabarcoding reveals metacommunity dynamics in a threatened boreal wetlandon May 12, 2020 at 10:12 am
The ability to accurately detect changes in ecosystem biodiversity caused by human activity has long challenged environmental scientists and ecologists, but a new study, published in PNAS, has ...
- Oxidized mitochondrial DNA sensing by STING signaling promotes the antitumor effect of an irradiated immunogenic cancer cell vaccineon May 12, 2020 at 1:32 am
Exposure to ionizing radiation, a physical treatment that inactivates live tumor cells, has been extensively applied to enhance the antitumor responses induced by cancer cell vaccines in both animal ...
- The Top 10 Technology Trends Of The 4th Industrial Revolutionon May 11, 2020 at 10:37 pm
We have never lived in a world of faster and more wide-reaching technology innovations. Our jobs, businesses, and how we operate as societies are being transformed by technology, and the current ...
- Illumina Nears Win In Bid To Block BGI's DNA Product Saleson May 11, 2020 at 7:43 pm
A California federal judge said Monday that he's inclined to grant Illumina's preliminary bid to block China-based BGI Genomics from selling DNA sequencing products accused of infringing its patents, ...
- Behavioral Science Technology For Advisorson May 10, 2020 at 4:01 pm
How a behavioral technology platform can be deployed inside financial services organizations for online behavioral management solutions to Know, Engage and Grow ...
- Eukaryotic DNA Polymerase Market Research Report 2020 : COVID-19 Impact Analysis And Predictive Business Strategy By Top Companieson May 9, 2020 at 3:33 am
Prudour Pvt. Ltd: Global Eukaryotic DNA Polymerase Market (Value, Production and Consumption), Ecosystem Analysis, Intellectual Property Analysis, Splits the Breakdown (Data Status 2012-2019 and ...
- DNA Leads To Arrest In 1987 Strangulation Of Teen Who Was Preparing To Be Maid Of Honor In Sister’s Weddingon May 8, 2020 at 12:25 pm
More than three decades after a music-loving Ohio teen was strangled to death, a man has been arrested and charged in connection with her horrific murder.
- New technique delivers complete DNA sequences of chromosomes inherited from mother and fatheron May 7, 2020 at 7:57 am
An international team of scientists led by the University of Adelaide's Davies Research Centre has shown that it is possible to disentangle the DNA sequences of the chromosomes inherited from the ...
- Applied DNA Schedules Fiscal 2020 Second Quarter Financial Results Conference Call for Thursday, May 14, 2020 at 4:30 PM ETon May 7, 2020 at 5:00 am
Applied DNA Sciences, Inc. (NASDAQ: APDN), announced today it plans to release financial results for its fiscal 2020 second quarter ended March 31, 20 ...
- BRIEF-Applied DNA Accepted Into U.S. FDA’S Emerging Technology Program, Creating Pathway For Molecular Tagging Of Pharmaceuticals And Packagingon April 30, 2020 at 2:06 pm
APPLIED DNA ACCEPTED INTO U.S. FDA’S EMERGING TECHNOLOGY PROGRAM, CREATING PATHWAY FOR MOLECULAR TAGGING OF PHARMACEUTICALS AND PACKAGING * APPLIED DNA - EMERGING TECHNOLOGY TEAM OF FDA ACCEPTED CO ...
via Bing News